Distinguish methadone maintenance from buprenorphine in terms of access, pharmacology, and safety.

• A. Methadone is a full agonist requiring licensed opioid treatment programs for dispensing; buprenorphine is a partial agonist that can be prescribed by qualified clinicians in office-based settings; both reduce relapse and mortality; risk of respiratory depression exists; buprenorphine has a ceiling effect
• B. Buprenorphine is a full agonist; Methadone is a partial agonist
• C. They are identical in pharmacology
• D. There is no difference between them

Answer: (A)

The core idea is how these two medications work in the body and how patients access them. Methadone is a full opioid agonist at the mu receptor, giving substantial opioid effects and carrying a higher risk of respiratory depression and overdose, especially if not carefully monitored. Because of safety and regulatory concerns, it is dispensed primarily through licensed opioid treatment programs, often with daily or highly supervised dosing, which limits access to settings with those programs.

Buprenorphine, by contrast, is a partial agonist at the mu receptor. It activates the receptor enough to alleviate withdrawal and cravings but has a ceiling effect that limits respiratory depression, making overdose risk lower. This safer pharmacology allows buprenorphine to be prescribed by qualified clinicians in office-based settings, broadening access to treatment.

Both medications improve outcomes by reducing relapse and lowering mortality, but they differ in how patients can receive care and their safety profiles. The statement reflects these distinctions: methadone as a full agonist with OTP-based dispensing, buprenorphine as a partial agonist usable in office-based care, with a safety advantage due to the ceiling effect.